Le pipeline 2023 des médicaments antirhumatismaux modificateurs de la maladie (DMARD) en développement clinique pour la spondylarthrite (y compris le rhumatisme psoriasique) : Une revue systématique des essais
RMD Open. 2023;9(3):e003279 doi 10.1136/rmdopen-2023-003279 https://pubmed.ncbi.nlm.nih.gov/37507210/
This systematic review identified DMARDs evaluated for axSpA and PsA, distinguishing between csDMARDs, tsDMARDs, and bDMARDs. The review pinpointed twenty-six distinct targeted therapies currently in clinical development; 18 therapies for axSpA and 15 therapies for PsA.